WO2025070702A1 - 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物 - Google Patents

抗体の産生方法、および抗体の産生方法において使用するための脂質組成物 Download PDF

Info

Publication number
WO2025070702A1
WO2025070702A1 PCT/JP2024/034593 JP2024034593W WO2025070702A1 WO 2025070702 A1 WO2025070702 A1 WO 2025070702A1 JP 2024034593 W JP2024034593 W JP 2024034593W WO 2025070702 A1 WO2025070702 A1 WO 2025070702A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
producing
lipid composition
formula
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/034593
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
達也 二田原
直人 中村
祐輔 十塚
広文 福永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Priority to JP2025549159A priority Critical patent/JPWO2025070702A1/ja
Publication of WO2025070702A1 publication Critical patent/WO2025070702A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Definitions

  • the present invention relates to a method for producing an antibody, which comprises administering a lipid composition containing DNA encoding an antigen protein to a non-human animal.
  • the present invention further relates to a lipid composition for use in the above-mentioned method for producing an antibody.
  • Patent Document 1 describes the production of antibodies by administering lipid nanoparticles made from mRNA and cationic lipids to non-human animals.
  • Patent Document 2 describes a method of complexing polynucleotides and cationic lipids and administering the complex to animals to induce an immune response.
  • Patent Document 3 describes that lipid particles prepared using a compound having a specific structure exhibit a high nucleic acid encapsulation rate and excellent nucleic acid delivery.
  • Patent Document 1 uses mRNA, and although the time from administration to translation is short, there is a problem that the durability of antigen expression is inferior to that of DNA. In addition, there is a problem that quality control is difficult due to the tendency of mRNA to decompose, and there is a problem that mRNA must be synthesized from DNA, making the manufacturing process complicated.
  • Patent Document 2 a commercially available cationic lipid (Lipofectamine) is used, but the cationic lipid is not optimized for antigen expression and immune induction by DNA.
  • the present invention aims to provide a method for producing antibodies using a lipid composition optimized for immunity, without using mRNA that has poor sustained antigen protein expression.
  • a further aim of the present invention is to provide a lipid composition optimized for immunity, without using mRNA that has poor sustained antigen protein expression.
  • lipid composition containing one or more compounds represented by the following formula (1) or formula (2) and DNA encoding an antigen protein can be administered to a non-human animal to produce antibodies in high yields.
  • the present invention was completed based on the above findings. According to the present invention, the following inventions are provided.
  • a method for producing an antibody comprising administering to a non-human animal a lipid composition comprising one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein.
  • a lipid composition comprising one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein.
  • the lipid composition further contains a phospholipid.
  • the phospholipid is at least one selected from the group consisting of dioleoylphosphatidylethanolamine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and stearoyloleoylphosphatidylcholine.
  • ⁇ 4> The method for producing an antibody according to ⁇ 1>, wherein the compound is a compound represented by formula (1).
  • ⁇ 5> The method for producing an antibody according to any one of ⁇ 1> to ⁇ 4>, wherein the lipid composition further contains a sterol.
  • ⁇ 6> The method for producing an antibody according to any one of ⁇ 1> to ⁇ 4>, wherein the lipid composition further contains a lipid having a nonionic hydrophilic polymer chain.
  • ⁇ 7> The method for producing an antibody according to any one of ⁇ 1> to ⁇ 4>, wherein the administration method is local administration.
  • ⁇ 8> The method for producing the antibody according to any one of ⁇ 1> to ⁇ 4>, further comprising fusing an antibody-producing cell obtained from the non-human animal to which the lipid composition has been administered with a proliferative cell to establish a hybridoma, and culturing the hybridoma.
  • the DNA is introduced into the cells, the antigen protein encoded by the DNA is expressed, and antibodies against the antigen protein can be produced.
  • FIG. 1 shows the results of measuring rabbit antibody production.
  • the method for producing an antibody according to the present invention comprises administering to a non-human animal a lipid composition comprising one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein.
  • the lipid composition comprises one or more compounds of formula (1) or formula (2).
  • the compound represented by formula (1) and the compound represented by formula (2) are compounds described in Example 25 and Example 125, respectively, of International Publication WO2019/235635.
  • the amount of one or more compounds represented by formula (1) or formula (2) is preferably 20 mol% to 80 mol% of the total lipid amount, more preferably 35 mol% to 70 mol%, and even more preferably 40 mol% to 65 mol%.
  • the lipid composition includes DNA encoding an antigenic protein.
  • Any antigen protein can be used as the antigen protein, but a transmembrane protein is particularly preferred.
  • the antigen protein is preferably a cancer antigen or a tumor antigen.
  • cancer antigens and tumor antigens are shown below, but is not limited to these.
  • antigens or their partial peptides can be used as antigen proteins.
  • CD2 CD19, CD20, CD22, CD27, CD33, CD37, CD38, CD40, CD44, CD47, CD52, CD56, CD70, CD79, CD137, 4-IBB, 5T4, AGS-5, AGS-16, angiopoietin 2, B7.1, B7.2, B7DC, B7H1, B7H2, B7H3, BT-062, BTLA, CAIX, carcinoembryonic antigen, CTLA4, Cripto, ED-B, ErbBl, ErbB2, ErbB3, ErbB4, EGFL7, EpCAM, EphA2, EphA3, EphB2, FAP, fibronectin, folate receptor, ganglioside GM3, GD2 , glucocorticoid-inducible tumor necrosis factor receptor (GITR), gplOO, gpA33, GPNMB, ICOS, IGF1R, integrin av, integrin ⁇ , LAG-3, Lewis
  • the form of the DNA encoding the antigen protein is not particularly limited, but an example is a plasmid expression vector for expressing the antigen protein in eukaryotic cells. Note that nanoplasmids, which are smaller than conventional plasmids, can also be used as plasmid expression vectors.
  • Expression vectors for eukaryotic cells generally contain four elements. The first element is a sequence encoding an origin of replication. This allows the plasmid to grow in the host. The second element is an element that controls the initiation of transcription, specifically a promoter sequence and, if desired, an enhancer sequence. The third element is a sequence involved in the processing of the transcript, such as a polyadenylation sequence. The fourth element is a sequence encoding the antigen protein.
  • the DNA encoding the antigen protein (which may be cDNA) can be functionally linked to the expression vector.
  • Two DNA sequences (a promoter sequence and a sequence encoding an antigenic protein) can be said to be operably linked if the linkage between them (1) does not result in the introduction of a frameshift mutation, (2) does not interfere with the ability of the promoter sequence to direct the transcription of an immunogen-encoding gene sequence, or (3) does not interfere with the ability of the sequence encoding an antigenic protein to be transcribed by the promoter sequence.
  • the promoter may be derived from a virus (e.g., adenovirus, bovine papilloma virus, simian virus, etc.), a mammalian promoter such as an actin, collagen, or myosin promoter, or a prokaryotic promoter (e.g., bacteriophage T3 RNA polymerase promoter).
  • a virus e.g., adenovirus, bovine papilloma virus, simian virus, etc.
  • a mammalian promoter such as an actin, collagen, or myosin promoter
  • a prokaryotic promoter e.g., bacteriophage T3 RNA polymerase promoter
  • promoters include the mouse metallothionein I gene promoter, herpes virus TK promoter, SV40 early promoter, Rous sarcoma virus promoter, and cytomegalovirus promoter.
  • the amount of DNA encoding the antigen protein is, for example, 0.01 to 50% by weight, preferably 0.1 to 30% by weight, and more preferably 0.5 to 15% by weight, based on the total lipid amount.
  • the lipid composition preferably further comprises a phospholipid.
  • the phospholipid is not particularly limited, but may be phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, etc., and is preferably phosphatidylcholine.
  • the phospholipid may be a single phospholipid or a combination of multiple different phospholipids.
  • Phosphatidylcholines include, but are not limited to, soybean lecithin (SPC), hydrogenated soybean lecithin (HSPC), egg yolk lecithin (EPC), hydrogenated egg yolk lecithin (HEPC), dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), dioleoyl phosphatidylcholine (DOPC), distearoyl phosphatidylcholine (DSPC), stearoyloleoyl phosphatidylcholine (SOPC), 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC), etc.
  • SPC soybean lecithin
  • HSPC hydrogenated soybean lecithin
  • EPC egg yolk lecithin
  • HEPC hydrogenated egg yolk lecithin
  • DMPC dimyristoyl phosphatidylcholine
  • DPPC dipalmitoyl phosphat
  • Phosphatidylethanolamines include, but are not limited to, dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dioleoylphosphatidylethanolamine (DOPE), dilinoleoylphosphatidylethanolamine (DLoPE), diphytanoylphosphatidylethanolamine (D(Phy)PE), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), ditetradecylphosphatidylethanolamine, dihexadecylphosphatidylethanolamine, dioctadecylphosphatidylethanolamine, diphytanylphosphatidylethanolamine, etc.
  • DMPE dimyristoylphosphatidylethanolamine
  • DPPE dipalmitoylphosphatidylethanolamine
  • DSPE di
  • Sphingomyelins include, but are not limited to, egg yolk-derived sphingomyelin and milk-derived sphingomyelin.
  • the phospholipid is preferably at least one selected from the group consisting of dioleoylphosphatidylethanolamine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, and stearoyloleoylphosphatidylcholine, with dioleoylphosphatidylethanolamine being particularly preferred.
  • the amount of phospholipids is preferably 3 mol% or more and 55 mol% or less of the total amount of the constituent lipid components.
  • the lipid composition preferably further contains a sterol, which can reduce membrane fluidity and provide a stabilizing effect for the lipid composition.
  • sterols include, but are not limited to, cholesterol, phytosterol (sitosterol), stigmasterol, fucosterol, spinasterol, brassicasterol, etc.), ergosterol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, etc.
  • cholesterol is preferred.
  • the amount of sterol is preferably 10 mol% to 60 mol% of the total lipid amount, more preferably 20 mol% to 55 mol%, and even more preferably 25 mol% to 50 mol%.
  • the lipid composition preferably further contains a lipid having a nonionic hydrophilic polymer chain.
  • a dispersion stabilization effect of the lipid composition can be obtained.
  • nonionic hydrophilic polymers include, but are not limited to, nonionic vinyl polymers, nonionic polyamino acids, nonionic polyesters, nonionic polyethers, nonionic natural polymers, nonionic modified natural polymers, and block or graft copolymers that have two or more of these polymers as building blocks.
  • nonionic hydrophilic polymers nonionic polyethers, nonionic polyesters, nonionic polyamino acids or nonionic synthetic polypeptides are preferred, nonionic polyethers or nonionic polyesters are more preferred, nonionic polyethers or nonionic monoalkoxy polyethers are even more preferred, and polyethylene glycol (polyethylene glycol will also be referred to as PEG below) is particularly preferred.
  • the lipid having a non-ionic hydrophilic polymer is not particularly limited, but includes PEG-modified phosphoethanolamine, diacylglycerol PEG derivative, dialkylglycerol PEG derivative, cholesterol PEG derivative, ceramide PEG derivative, etc. Among these, diacylglycerol PEG is preferred.
  • the weight average molecular weight of the PEG chain of the nonionic hydrophilic polymer derivative is preferably 500 to 5,000, and more preferably 750 to 3,000.
  • the non-ionic hydrophilic polymer chain may be branched and may have a substituent such as a hydroxymethyl group.
  • the amount of lipid having a nonionic hydrophilic polymer chain is preferably 0.25 mol% to 12 mol% of the total lipid amount, more preferably 0.5 mol% to 6 mol%, and even more preferably 1 mol% to 3 mol%.
  • a lipid composition comprising one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein can be used for use in the method for producing an antibody according to the present invention. That is, according to the present invention, there is provided a lipid composition for use in the method for producing an antibody according to the present invention, comprising one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein.
  • the method for producing the lipid composition is not limited, but the lipid composition can be produced by dissolving all or a part of the oil-soluble components of the lipid composition in an organic solvent or the like to form an oil phase, dissolving water-soluble components such as DNA in water to form an aqueous phase, and mixing the oil phase and the aqueous phase.
  • a micromixer may be used for mixing, or the lipid composition may be emulsified using an emulsifier such as a homogenizer, an ultrasonic emulsifier, a high-pressure jet emulsifier, or the like.
  • a lipid-containing solution can be dried under reduced pressure using an evaporator or spray-dried using a spray dryer to prepare a dried mixture containing lipids, which can then be added to an aqueous solvent and emulsified using the emulsifier described above.
  • An example of a method for producing a lipid composition containing DNA is Step (a) of dissolving the components of the lipid composition in an organic solvent to obtain an oil phase; (b) mixing the oil phase obtained in (a) with an aqueous phase containing DNA; (c) diluting the mixture containing the oil phase and the aqueous phase obtained in step (b) to obtain a dispersion of lipid particles; (d) removing the organic solvent from the lipid particle dispersion obtained in the step (c); and (e) adjusting the concentration of the lipid particle dispersion obtained in the step (d);
  • the method includes the steps of:
  • Step (a) involves dissolving components classified as lipids in an organic solvent (an alcohol such as ethanol, or an ester, etc.).
  • the total lipid concentration after dissolution in the organic solvent is not particularly limited, but is generally 1 mmol/L to 100 mmol/L, preferably 5 mmol/L to 50 mmol/L, and more preferably 10 mmol/L to 30 mmol/L.
  • the aqueous phase can be obtained by dissolving DNA in water or a buffer solution.
  • concentration of DNA is not particularly limited, but is preferably 1 to 1000 ⁇ g/mL, and more preferably 10 to 500 ⁇ g/mL. If necessary, components such as buffer components for pH adjustment and antioxidants can be added.
  • the pH of the aqueous phase is preferably 2.0 to 7.0, and more preferably 3.0 to 6.0. To adjust the pH to the above range, acetic acid, citric acid, malic acid, phosphoric acid, MES, HEPES, etc.
  • salts such as sodium chloride and potassium chloride may be added to adjust the salt strength
  • sugars and sugar alcohols such as sucrose, trehalose, and mannitol may be added to adjust the osmotic pressure.
  • the oil phase and the aqueous phase may be mixed by any method, including a batch method or an in-line method using a flow path device.
  • a micro flow path device is preferably used, and examples of the micro flow path device that can be used include a Y-shaped mixer, a T-shaped mixer, a herringbone mixer, a ring micro mixer, and an impingement jet mixer.
  • the mixing ratio (volume ratio) of the aqueous phase to the oil phase is preferably 5:1 to 1:1, and more preferably 4:1 to 2:1.
  • the lipid particle dispersion is mixed with a diluent solution to reduce the organic solvent content and stabilize the lipid particles.
  • the diluent solution may be water, but may also include adjusting the pH or salt strength.
  • the components contained in the diluent solution may be selected arbitrarily depending on the purpose.
  • a buffer solution e.g., citrate buffer, citrate buffered saline, acetate buffer, acetate buffered saline, phosphate buffered saline, Tris buffer, MES buffer, HEPES buffer, etc.
  • a buffer solution e.g., citrate buffer, citrate buffered saline, acetate buffer, acetate buffered saline, phosphate buffered saline, Tris buffer, MES buffer, HEPES buffer, etc.
  • sodium chloride, potassium chloride, sucrose, trehalose, fructose, mannitol, etc. may be included for the purpose of adjusting the salt strength or osmotic pressure, and the above buffer solutions to which these additives have been further added may also be used.
  • the lipid particle dispersion and the dilution solution may be mixed by any method, including a batch method or an in-line method using a flow path device.
  • the flow path device used for mixing may be a Y-shaped mixer, a T-shaped mixer, or the like.
  • the mixing ratio (liquid volume ratio) of the lipid particle dispersion and the dilution solution is preferably 1:0.5 to 1:10, and more preferably 1:1 to 1:5.
  • the lipid particle dispersion in step (c), may be mixed with the dilution solution multiple times depending on the purpose.
  • the dilution solutions used may be the same or different.
  • the particle size of the lipid particles may change depending on the pH, so adjusting the pH of the dispersion is important. Therefore, for example, in order to adjust the pH of the lipid particle dispersion after mixing with the dilution solution, a buffer solution having an appropriate concentration and pH, or a buffer solution containing other components, may be used.
  • the interval between one dilution step and the next dilution step may be set arbitrarily, for example, the interval may be 10 seconds, 30 seconds, 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, or 24 hours.
  • the pH of the lipid particle dispersion after step (c) is preferably from pH 3.0 to 10.0, more preferably from pH 3.5 to pH 9.0, and particularly preferably from pH 4.0 to pH 8.5.
  • the lipid particles can be subjected to sizing as necessary.
  • the method of sizing is not particularly limited, but the particle size can be reduced by using an extruder or the like.
  • the dispersion liquid containing the lipid particles can be subjected to freezing or freeze-drying by a general method.
  • the method for removing the organic solvent from the lipid particle dispersion is not particularly limited and any common method can be used.
  • the organic solvent can be removed by dialysis using a pH buffer solution such as phosphate buffered saline or Tris buffer as the dialysis fluid.
  • additives such as any salt or sugar can be added for the purpose of adjusting the osmotic pressure or protecting the dispersion from freezing.
  • step (e) the concentration of the dispersion obtained in step (d) can be adjusted.
  • concentration of the dispersion obtained in step (d) can be adjusted.
  • phosphate buffered saline, saline, Tris-HCl buffer, or the like can be used as a diluent to dilute to an appropriate concentration.
  • the dispersion obtained in step (d) can be concentrated by ultrafiltration using an ultrafiltration membrane. The concentrated dispersion can be used as is, or it can be concentrated and then adjusted to the desired concentration using the diluent.
  • the organic solvent removal step (step (d)) and the concentration adjustment step (step (e)) can be carried out continuously using tangential flow filtration (TFF).
  • TDF tangential flow filtration
  • the organic solvent removal step and the concentration adjustment step may be carried out in any order. If necessary, the organic solvent removal step and the concentration adjustment step may each be carried out multiple times.
  • the solution that can be used for dialysis in step (d) and dilution in step (e) may contain excipients, cryoprotectants, buffers, and antioxidants.
  • excipients and cryoprotectants include, but are not limited to, sugars and sugar alcohols.
  • sugars include sucrose, trehalose, maltose, glucose, lactose, and fructose
  • sugar alcohols include mannitol, sorbitol, inositol, and xylitol.
  • buffers include, but are not limited to, ACES, BES, Bicine, CAPS, CHES, DIPSO, EPPS, HEPES, HEPPSO, MES, MOPS, MOPSO, TAPS, TAPSO, TES, Tricine, Tris, phosphoric acid, acetic acid, and citric acid.
  • antioxidants include EDTA, ascorbic acid, and tocopherol.
  • lipid particle dispersion In order to make the lipid particle dispersion into a cancer treatment agent, it is preferable to carry out sterile filtration.As a filtration method, it is possible to remove unnecessary substances from the lipid particle dispersion using a hollow fiber membrane, a reverse osmosis membrane, a membrane filter, etc.In the present invention, although not particularly limited, it is preferable to carry out filtration using a filter with a pore size that can be sterilized (preferably a 0.2 ⁇ m filter sterilization filter).In addition, it is preferable to carry out sterile filtration after step (c) or step (d) or step (e). Furthermore, if necessary, the lipid particle dispersion can be subjected to freeze-drying.
  • the lipid composition may be a lipid particle.
  • the lipid particle means a particle composed of lipid, and includes a composition having any structure selected from lipid aggregates, micelles, and liposomes, but the structure of the lipid particle is not limited to these as long as it is a composition containing lipid.
  • the liposome has a lipid bilayer structure, has an aqueous phase inside, and includes a single-layered liposome with a bilayer membrane and a multi-layered liposome with multiple layers. Either type of liposome may be included in the present invention.
  • the morphology of lipid particles can be confirmed by electron microscopy or structural analysis using X-rays. For example, by using a cryo-transmission electron microscope (cryo-TEM) it can be confirmed whether the lipid particles have a lipid bilayer structure (lamellar structure) and an inner water layer like liposomes, or whether the particles have a core with high electron density inside and are packed with lipids and other components. Small angle X-ray scattering (SAXS) measurements can also be used to confirm whether lipid particles have a lipid bilayer structure (lamellar structure).
  • SAXS Small angle X-ray scattering
  • the particle size of the lipid particles is not particularly limited, but is preferably 10 to 1000 nm, more preferably 30 to 500 nm, and even more preferably 50 to 250 nm.
  • the particle size of the lipid particles can be measured by a general method (e.g., dynamic light scattering method, laser diffraction method, etc.).
  • lipid compositions to non-human animals
  • a lipid composition containing one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein is administered to a non-human animal.
  • the lipid composition containing one or more compounds represented by formula (1) or formula (2) and DNA encoding an antigen protein may be administered to humans.
  • the lipid composition can be administered to the living body alone or mixed with an administration vehicle (e.g., saline or a buffer solution).
  • an administration vehicle e.g., saline or a buffer solution.
  • the non-human animal is preferably a non-human mammal, for example, rabbit, mouse, rat, monkey, etc., with rabbit and mouse being preferred.
  • Methods of administration to non-human animals include systemic administration or local administration, with local administration being preferred. Local administration includes intramuscular injection, subcutaneous injection, intradermal injection, and the like.
  • the dosage of the lipid composition to a non-human mammal is preferably such that the dosage of the encapsulated DNA is 1 to 1000 ⁇ g/head, and more preferably 3 to 500 ⁇ g/head. In addition, it is preferable to administer the composition once every 1 to 4 weeks.
  • Antibodies against antigen proteins are produced in the body of a non-human animal to which the lipid composition has been administered. Therefore, blood can be taken from the non-human animal to which the lipid composition has been administered, and the produced antibodies can be collected.
  • antibody-producing cells obtained from a non-human animal to which a lipid composition has been administered may be fused with proliferative cells to establish hybridomas, and the hybridomas may be cultured to produce antibodies.
  • antibody is used in the broadest sense to mean an immunoglobulin molecule that recognizes and specifically binds to an antigenic protein via at least one antigen recognition site in the variable region of the immunoglobulin molecule.
  • the antibodies may be either polyclonal or monoclonal, either multiple chain or single chain or intact immunoglobulins.
  • An intact antibody is typically a glycoprotein comprising at least two heavy (H) and two light (L) chains linked together by disulfide bonds.
  • Each heavy chain is composed of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region.
  • the heavy chain constant region comprises three domains, CH1, CH2 and CH3.
  • Each light chain is composed of a light chain variable region (abbreviated as VL) and a light chain constant region.
  • the light chain constant region is composed of one domain, CL.
  • the VH and VL regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • variable regions of the heavy and light chains contain a binding domain that interacts with an antigenic protein.
  • the constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (C1q) of the classical complement system.
  • Antibodies can be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass.
  • Test Example 1 Preparation of plasmid DNA-encapsulating lipid nanoparticles and measurement of antibody production in mice ⁇ Phospholipids used> DOPE (L- ⁇ -dioleoyl phosphatidylethanolamine) and SOPC (1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine) were purchased from NOF Corporation.
  • DOPE Li- ⁇ -dioleoyl phosphatidylethanolamine
  • SOPC 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine
  • Plasmid DNA (Fujifilm Wako Pure Chemical Industries, Ltd.) encoding hEphA2 (Erythropoietin producing hepatoma receptor-A2) was diluted with 50 mmol/L citrate buffer at pH 4.0 so that the weight ratio of total lipid concentration to plasmid DNA concentration was approximately 20:1 to obtain an aqueous phase.
  • PBS phosphate-buffered saline
  • This dispersion was dialyzed against 20 mM Tris buffer containing 8% sucrose using a dialysis cassette (Slide-A-Lyzer G2, MWCO: 10 kD, Thermo Fisher Scientific) to remove ethanol, and then concentrated using an ultrafiltration filter (Amicon Ultra 100 kDa, Merck) to obtain lipid nanoparticles encapsulating plasmid DNA.
  • a dialysis cassette Slide-A-Lyzer G2, MWCO: 10 kD, Thermo Fisher Scientific
  • an ultrafiltration filter Amicon Ultra 100 kDa, Merck
  • the particle size of the plasmid DNA-encapsulated lipid nanoparticles was measured using a particle size measuring device NanoSAQLA (Otsuka Electronics) after diluting 20 times with phosphate buffered saline (PBS).
  • the zeta potential was measured using a zeta potential measuring device ELS-Z2 (Otsuka Electronics) after diluting with HEPES buffer (pH 7.5) or MES buffer (pH 5.5). The results are shown in Table 2.
  • Plasmid DNA was diluted with MilliQ water to prepare a 2-fold dilution series from 100 ⁇ g/mL to 3.1 ⁇ g/mL, and a calibration curve solution was prepared. 50 ⁇ L of the calibration curve solution or plasmid DNA lipid nanoparticles diluted 10-fold with MilliQ water was mixed with 450 ⁇ L of methanol to prepare a measurement solution.
  • the absorbance of each measurement solution was measured at 260 nm and 330 nm using a UV plate reader (Multiskan Go, Thermo Fisher Scientific), and the absorbance of each measurement solution was determined by subtracting the absorbance at 330 nm from the absorbance at 260 nm.
  • the total aqueous phase nucleic acid concentration was calculated from the calibration curve using the absorbance of each sample measurement solution.
  • the nucleic acid concentration in the external aqueous phase was quantified by the standard addition method using Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher Scientific).
  • the 20x TE buffer included in the above kit was diluted with water to make 1x TE buffer.
  • TE stands for Tris/EDTA (ethylenediaminetetraacetic acid).
  • Plasmid DNA was diluted with TE buffer to a final concentration of 0 to 400 ng/mL to prepare a nucleic acid dilution series.
  • nucleic acid encapsulation rate (total plasmid DNA concentration - plasmid DNA concentration in external aqueous phase) ⁇ total plasmid DNA concentration ⁇ 100
  • mice Female, 6 weeks old
  • mice were allowed to acclimate for one week, and then the dispersion of plasmid DNA lipid nanoparticles prepared in the above ⁇ Preparation of plasmid DNA-encapsulating lipid nanoparticles>, or CaLiVax (OZ biosciences, CV02000) mixed with plasmid DNA according to the recommended protocol as Comparative Example 1, was administered intradermally to give a plasmid DNA dose of 42 or 14 ⁇ g/head (week 0; hereinafter referred to as W00). Thereafter, administration was repeated in the same manner every two weeks until W08. Blood was collected from the tail vein at the timing of W07 and 11, and serum was collected.
  • the obtained serum was diluted 200 times, and then added to CHO cells (MOCK) and CHO cells expressing hEphA2 protein, and reacted for 30 minutes, after which a fluorescently labeled secondary antibody (SouthernBiotech, 1030-09) was added.
  • the addition of serum and secondary antibody to the MOCK cells was used to quantify nonspecific adsorption.
  • the median fluorescent intensity (MFI) per cell of the above-treated CHO cells was then quantified by flow cytometry (Beckman Coulter, CytoFlex).
  • the MFI value of each Example was calculated by subtracting the MFI of the Mock cells from the MFI of the CHO cells expressing hEphA2 protein, and the ratio of the MFI to that of the Comparative Example was taken as the relative antibody production amount.
  • ⁇ Rabbit antibody production measurement> After purchasing rabbits (Japanese White Rabbits, female, 12 weeks old), they were allowed to acclimate for one week, and then CNE-CPO (OZ biosciences, CNE-1000) prepared in the above ⁇ Preparation of Plasmid DNA-Encapsulating Lipid Nanoparticles> as Example 1 or Comparative Example 3 was administered intradermally on the back or intramuscularly in the thigh at a plasmid DNA dose of 200 ⁇ g/head (week 0; hereinafter referred to as W00). Thereafter, administration was repeated every two weeks until W10. Blood was collected from the ear vein at the timing of W03, 05, 07, 09, and 11, and serum was collected.
  • the obtained serum was diluted 1000-fold, and then added to CHO cells (MOCK) and CHO cells expressing hEphA2 protein, and after 30 minutes of reaction, a fluorescently labeled secondary antibody (SouthernBiotech, 4030-09) was added.
  • the serum and secondary antibody were added to MOCK cells to quantify non-specific adsorption.
  • the median fluorescence intensity (MFI) per cell of the above-treated CHO cells was quantified by flow cytometry (Beckman Coulter, CytoFlex).
  • the MFI value of each example was calculated by subtracting the MFI of the mock cells from the MFI of the CHO cells expressing hEphA2 protein, and this was used as the amount of antibody production.
  • the physical properties of Example 1 are shown in Table 5, and the results of antibody production are shown in Table 6 and FIG.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2024/034593 2023-09-27 2024-09-27 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物 Ceased WO2025070702A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025549159A JPWO2025070702A1 (cg-RX-API-DMAC7.html) 2023-09-27 2024-09-27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-164924 2023-09-27
JP2023164924 2023-09-27

Publications (1)

Publication Number Publication Date
WO2025070702A1 true WO2025070702A1 (ja) 2025-04-03

Family

ID=95201687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/034593 Ceased WO2025070702A1 (ja) 2023-09-27 2024-09-27 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物

Country Status (2)

Country Link
JP (1) JPWO2025070702A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025070702A1 (cg-RX-API-DMAC7.html)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
JP2019528312A (ja) * 2016-08-07 2019-10-10 ノバルティス アーゲー mRNA媒介性の免疫化方法
WO2019235635A1 (ja) * 2018-06-08 2019-12-12 富士フイルム株式会社 化合物またはその塩および脂質粒子
WO2020246581A1 (ja) * 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
WO2021095876A1 (ja) * 2019-11-15 2021-05-20 富士フイルム株式会社 脂質組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
JP2019528312A (ja) * 2016-08-07 2019-10-10 ノバルティス アーゲー mRNA媒介性の免疫化方法
WO2019235635A1 (ja) * 2018-06-08 2019-12-12 富士フイルム株式会社 化合物またはその塩および脂質粒子
WO2020246581A1 (ja) * 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
WO2021095876A1 (ja) * 2019-11-15 2021-05-20 富士フイルム株式会社 脂質組成物

Also Published As

Publication number Publication date
JPWO2025070702A1 (cg-RX-API-DMAC7.html) 2025-04-03

Similar Documents

Publication Publication Date Title
JP2022101548A (ja) ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用
EP2184355A1 (en) Antibody modified with hydrophobic molecule
KR102554634B1 (ko) L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171)
NZ756016A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
EP4496587A1 (en) Lipid based nanoparticles for targeted gene delivery to the brain
CN109498817B (zh) 一种多细胞靶向脂质体
US12097265B2 (en) Cytotoxic particles for targeting P2X7 receptor
US20210246424A1 (en) Method of producing car-t cells, nucleic acid-introducing carrier and kit
Wöll et al. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells
WO2026103958A1 (zh) 脂质纳米颗粒偶联物及其制备方法和用途
US20060088538A1 (en) Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
US20230181471A1 (en) Concentrated compositions of proteins, their preparation and use thereof
WO2026040957A1 (zh) Cd117抗体及其应用
JP2007252372A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
US20250381150A1 (en) Lipid nanoparticles
WO2016167367A1 (ja) 標的化両親媒性ナノキャリア及びその製造方法
WO2026096836A1 (en) Lipid nanoparticles targeting central nervous system endothelial cells
WO2026062193A1 (en) Compositions and methods
Brown Anti-GD2 Etoposide-Loaded Immunoliposomes for the Treatment of GD2 Positive Tumors
JP2025534663A (ja) 治療薬の標的化送達のための組成物及び方法
WO2024081641A2 (en) Methods for preparing protein-conjugated nanocarriers
EP1988162A1 (en) Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent
JP2026046749A (ja) Car-t細胞の増殖方法、並びに、該方法に使用する脂質粒子及びキット
WO2025043547A9 (zh) T细胞导向免疫脂质体及其用途
WO2006030602A1 (ja) 卵巣癌の診断および/または治療薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24872484

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025549159

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025549159

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE